News | Contrast Media | November 04, 2019

The MRI contrast agent Clariscan (gadoterate meglumine) is now FDA approved for injection for intravenous use

The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio

November 4, 2019 – The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists. Clariscan is a gadolinium-based contrast agent indicated for intravenous use with MRI in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Clariscan has been approved in more than 55 countries globally and has had more than four million patient doses shipped in those countries. It is the latest in a growing range of imaging agents available in the U.S. from GE Healthcare. For more than 40 years, GE agents have been routinely used across MRI, X-ray/ computed tomography (CT) and ultrasound to enhance the image and support diagnosis.

“Demand for contrast media has significantly increased over the past decade. The introduction of Clariscan increases our clinical offering for U.S. radiologists, enhancing visualization to provide better patient care. Our customers rely on our high-quality products, first-rate supply network, and surrounding services to support their day-to-day work,” explained Kevin O’Neill, president and CEO Pharmaceutical Diagnostics at GE Healthcare.

“The FDA’s approval of this macrocyclic MR agent adds to the range of contrast media options available here in the U.S. and as radiologists we welcome this broader choice,” said Lawrence N Tanenbaum, M.D., FACR

GE Healthcare offers diagnostic imaging agents used in approximately 90 million procedures per year globally, equivalent to three patients every second. In the U.S., GE Healthcare has a strong record of innovation in new contrast media products and indications, with recent FDA approvals for Omnipaque (iohexol) in CT of the abdomen and for Visipaque (iodixanol) in coronary CT angiography. GE Healthcare has invested $240 million in its global manufacturing and supply network over the past five years to deliver imaging agents to hospitals and pharmacies globally.

Clariscan is manufactured in Norway using a proprietary manufacturing process. As with all GE Healthcare contrast media products, all stages of manufacturing, from development of the active pharmaceutical ingredient (API) to finished product, are managed entirely by GE Healthcare. Clariscan is available in single dose vials of 10, 15 and 20 mL. The packaging contains a 2D data matrix (barcode) on every Clariscan pack, which conveys key information, including national drug code number, individual lot number, and expiration date. This information can be easily scanned and uploaded onto electronic medical systems, helping to reduce the risk of manual data entry errors and helping workflow efficiencies at medical centers. 

For more information: https://corporate.gehealthcare.com/ 

Related content:

VIDEO: Managing Gadolinium Safety

Strategies to Lower CT Contrast Dose and Track Usage

Nurse Injured in MRI Accident at Swedish Hospital

Indian Man Killed in MRI Accident


Related Content

News | Magnetic Resonance Imaging (MRI)

September 28, 2023 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Magnetom ...

Time September 28, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
News | Lung Imaging

September 26, 2023 — In a study of more than 2,000 chest X-rays, radiologists outperformed AI in accurately identifying ...

Time September 26, 2023
arrow
News | Point-of-Care Ultrasound (POCUS)

September 26, 2023 — Exo (pronounced “echo”), a medical imaging software and device company, today unveiled a category ...

Time September 26, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
News | Artificial Intelligence

September 25, 2023 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, today announced ...

Time September 25, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
News | Cardiac Imaging

September 21, 2023 — Declines in cardiovascular procedure volumes observed early in the COVID-19 pandemic greatly ...

Time September 21, 2023
arrow
News | X-Ray

September 21, 2023 — Scientists in Moscow have successfully engineered a prototype detector for X-ray and PET/CT ...

Time September 21, 2023
arrow
Subscribe Now